July 09, 2025
Article
The phase 3 SUPRAME trial is comparing IMA203 vs investigator’s choice of therapy in patients with pretreated unresectable or metastatic cutaneous melanoma.
June 30, 2025
Podcast
Justin Moser, MD, discusses the ongoing phase 3 SUPRAME trial investigating IMA203 in previously treated, unresectable or metastatic cutaneous melanoma.
June 25, 2025
Video
Justin Moser, MD, discusses the design and implications of the SUPRAME trial investigating IMA203 in pretreated advanced cutaneous melanoma.
June 11, 2025
Article
Jason J. Luke, MD, FACP, discusses data for the PRAME-targeted TCR T-cell therapy IMA203 in advanced or metastatic melanoma.
June 06, 2025
Video
Jason Luke, MD, discusses IMA203 vs investigator’s choice of standard therapy in patients with previously treated advanced cutaneous melanoma.
June 05, 2025
Article
IMA203 was well tolerated and elicited durable responses in patients with advanced melanoma.